Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL 5 versus DEXTROAMPHETAMINE SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL 5 versus DEXTROAMPHETAMINE SULFATE.
ADDERALL 5 vs DEXTROAMPHETAMINE SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall 5 is a combination of dextroamphetamine and amphetamine, which are central nervous system stimulants. They increase the levels of dopamine and norepinephrine in the synaptic cleft by inhibiting their reuptake and promoting their release from presynaptic neurons.
Increases extracellular levels of norepinephrine and dopamine by blocking reuptake and promoting release from presynaptic terminals, via trace amine-associated receptor 1 (TAAR1) agonism and vesicular monoamine transporter 2 (VMAT2) inhibition.
Initial: 5 mg orally once or twice daily; increase by 5 mg increments at weekly intervals. Maximum: 40 mg/day in divided doses.
5-60 mg/day orally divided every 4-6 hours, starting at 5 mg once or twice daily.
None Documented
None Documented
Immediate-release: 9–11 hours (mean 10 hours for dextroamphetamine); extended-release: 10–13 hours. Terminal half-life may be prolonged with urinary pH >7.
9-11 hours (adults); clinical context: twice-daily dosing achieves steady-state in ~2-3 days.
Renal (90% as unchanged drug and metabolites; ~30% unchanged), minor fecal elimination (<5%).
Primarily renal (30-50% unchanged at acidic pH, less at alkaline pH); ~50% as metabolites (mostly deaminated and hydroxylated); minimal biliary/fecal.
Category C
Category D/X
CNS Stimulant
CNS Stimulant